Novo Nordisk Commits €432m to Monksland Upgrade for Oral Wegovy Production by 2028
Novo Nordisk is investing €432m to upgrade its Monksland, Athlone facility for oral Wegovy production, expanding a 45-acre tabletting site with 260 staff. The upgrade, slated for completion by 2028, aims to boost oral GLP-1RA capacity as FDA-approved Wegovy pill demand accelerates globally.
1. Facility Upgrade Investment
Novo Nordisk is allocating €432m to upgrade its Monksland, Athlone facility on a 45-acre site, retrofitting existing tabletting lines to produce oral semaglutide (Wegovy pill). The investment leverages the site’s 260 employees to expand manufacturing of GLP-1 receptor agonists outside the US.
2. Timeline and Capacity Expansion
Construction is underway and scheduled for completion by 2028, enhancing annual oral GLP-1RA output. The upgrade will bolster production capacity to meet expected global demand following FDA approval of the Wegovy pill and pending EU and UK authorizations.
3. Strategic Growth and Competitive Positioning
This Athlone expansion complements a $4.1bn facility planned in North Carolina and positions Novo Nordisk to scale oral GLP-1RA supply as rivals like Eli Lilly also invest heavily in manufacturing. Oral Wegovy sales are projected to exceed $4.5bn annually by 2031.